Authors:
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Anindo Saha,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Joeran S. Bosma,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Jasper J. Twilt,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Alexander B. C. D. Ng,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Aqua Asif,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Kirti Magudia,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Peder Larson,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Qinglin Xie,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Xiaodong Zhang,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Chi Pham Minh,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Samuel N. Gitau,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Ivo G. Schoots,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Martijn F. Boomsma,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Renato Cuocolo,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Nikolaos Papanikolaou,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Daniele Regge,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Derya Yakar,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Mattijs Elschot,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Jeroen Veltman,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Baris Turkbey,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Nancy A. Obuchowski,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Jurgen J. Fütterer,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Anwar R. Padhani,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Hashim U. Ahmed,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Tobias Nordström,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Martin Eklund,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Veeru Kasivisvanathan,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Maarten de Rooij,
on behalf of the PI-CAI, ProCAncer-I, COMFORT, STHLM3-MRI and PRIME consortia Henkjan Huisman
In this intercontinental, confirmatory study, we include a retrospective cohort of 22,481 MRI examinations (21,288 patients; 46 cities in 22 countries) to train and externally validate the PI-CAI-2B model, i.e., an efficient, next-generation iteration of the state-of-the-art AI system that was developed for detecting Gleason grade group $\geq$2 prostate cancer on MRI during the PI-CAI study. Of these examinations, 20,471 cases (19,278 patients; 26 cities in 14 countries) from two EU Horizon projects (ProCAncer-I, COMFORT) and 12 independent centers based in Europe, North America, Asia and Africa, are used for training and internal testing. Additionally, 2010 cases (2010 patients; 20 external cities in 12 countries) from population-based screening (STHLM3-MRI, IP1-PROSTAGRAM trials) and primary diagnostic settings (PRIME trial) based in Europe, North and South Americas, Asia and Australia, are used for external testing. Primary endpoint is the proportion of AI-based assessments in agreement with the standard of care diagnoses (i.e., clinical assessments made by expert uropathologists on histopathology, if available, or at least two expert urogenital radiologists in consensus; with access to patient history and peer consultation) in the detection of Gleason grade group $\geq$2 prostate cancer within the external testing cohorts. Our statistical analysis plan is prespecified with a hypothesis of diagnostic interchangeability to the standard of care at the PI-RADS $\geq$3 (primary diagnosis) or $\geq$4 (screening) cut-off, considering an absolute margin of 0.05 and reader estimates derived from the PI-CAI observer study (62 radiologists reading 400 cases). Secondary measures comprise the area under the receiver operating characteristic curve (AUROC) of the AI system stratified by imaging quality, patient age and patient ethnicity to identify underlying biases (if any).
Subjects:
Image and Video Processing
,
Computer Vision and Pattern Recognition
Publish: 2025-08-04 15:39:31 UTC